对于业绩变动的原因，君实生物表示，营业收入同比增长主要系商业化药品的销售收入与上年同期相比 增长，其中，拓益®于国内市场实现销售收入约9.54亿元，同比增长约42%。截至报告期末，拓益®已 累计在全国超过六千家医疗机构及超过三千家专业药房和社会药房销售。 另外，君实生物还提到，今年上半年，其归属于上市公司股东的净利润、基本每股收益、稀释每股收益 较上年同期亏损减少，主要系商业化药品的销售收入与上年同期相比有所增长。同时，公司进一步落 实"提质增效重回报"行动方案，聚焦更有竞争优势和更有创新性的研发项目，加快临床开发、降低生产 成本、提升销售效率，减少亏损；经营活动产生的现金流量净额较上年同期净流出减少，主要系商业化 药品的销售收入增加，同时本期收到较大金额的技术许可款项。 作为一家创新医药公司，君实生物的创新领域已从单抗药物类型持续扩展至包括小分子药物、抗体偶联 药物（ADC）、双特异性或多特异性抗体药物、融合蛋白、核酸类药物、疫苗等更多类型的药物研 发，以及针对癌症、自身免疫性疾病等下一代创新疗法的探索。 君实生物在研产品管线覆盖五大治疗领域，包括恶性肿瘤、自身免疫系统疾病、慢性代谢类疾病、神经 系统类疾病 ...

Core Viewpoint - The company has expanded its innovative research and development from monoclonal antibodies to a broader range of drug types, including small molecules, peptides, antibody-drug conjugates (ADCs), bispecific or multispecific antibodies, fusion proteins, and nucleic acid drugs, focusing on next-generation innovative therapies for cancer and autoimmune diseases [1] Group 1: Product Pipeline and Therapeutic Areas - The company's product pipeline covers five major therapeutic areas: malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases [1] - Currently, the company has four commercialized drugs: Tuoyi® (特瑞普利单抗), Junmai Kang® (君迈康), Mindewi® (民得维), and Junshida® (君适达) [1] - Nearly 30 drug candidates are in clinical trial stages, with over 20 candidates in preclinical development [1] Group 2: Regulatory Approvals and Market Access - The core product Tuoyi® has received approval for 12 indications in mainland China, with 10 of these indications included in the national medical insurance catalog [1] - The company is accelerating the development and market application of late-stage pipeline products, including anti-BTLA monoclonal antibody tifcemalimab (TAB004/JS004), anti-IL-17A monoclonal antibody (JS005), subcutaneous PD-1 monoclonal antibody formulation (JS001sc), and PD-1/VEGF bispecific antibody (JS207) [1] Group 3: Early-stage Pipeline Exploration - The company continues to explore early-stage pipeline products, including anti-Claudin18.2 ADC (JS107), PI3K-α oral small molecule inhibitor (JS105), CD20/CD3 bispecific antibody (JS203), anti-DKK1 monoclonal antibody (JS015), EGFR/HER3 bispecific antibody conjugate (JS212), and PD-1/IL-2 bifunctional antibody fusion protein (JS213) [1]